This is a working overview of prothymosin alpha, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-07-27. Anything still debated is marked as such rather than presented as settled.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
This mechanism serves as a source of protection for the amino group in the amino acid. The ester will block the amino group from binding with other molecules. The last step in this reaction is the cyclization of the N-haloacylamino acids with an acetanhydride. This will result in the expected azlactone (3).
Any cardiovascular disease including: Moderate to severe hypertension Atrial fibrillation Atrial flutter Ventricular tachycardia Ventricular fibrillation Ventricular flutter Advanced arteriosclerosis Severe cardiovascular disorders Uncontrolled hyperthyroidism Pheochromocytoma or history thereof Concomitant treatment with monoamine oxidase inhibitors (MAOIs) (and with at least 2 weeks washout) Narrow-angle glaucoma Pregnancy and lactation Hypersensitivity to atomoxetine or other constituents However, the FDA label states that in the case of cardiovascular disease, atomoxetine is only contraindicated in the case of severe cardiovascular disease. However, it states that atomoxetine should be used with caution in people with cardiovascular disease. In addition, consideration should be given to not using atomoxetine in people with clinically significant or serious structural cardiac abnormalities, as this may put them at greater risk of cardiovascular complications with atomoxetine. A precaution or relative contraindication is concomitant use of strong CYP2D6 inhibitors, which may necessitate atomoxetine dose adjustment.
== Dominican studies == Peukert was fluent in Spanish, and was very interested in the history of Latin America, especially the Dominican Republic, which he spent much of the late 1980s visiting. As the name Detlev is hard for Spanish speakers to pronounce, Peukert took to calling himself "Julio" Peukert. Peukert was interested in youth policy in the Dominican Republic and spent much time in the barrios (slums) of Santo Domingo working as a volunteer helping poor teenagers. In 1986, Peuket published a book in Spanish Anhelo de Dependencia Las Ofertas de Anexion de la Republica Dominicana a los Estados Unidos en siglo XIX about the debate concerning American plans to annex the Dominican Republic in the 19th century. Always a politically engaged historian, Peukert engaged in city planning for Santo Domingo and criticized the Dominican government for not doing more to help with the problems of poverty. At the time of his death, Peukert had begun writing a biography of the Dominican dictator General Rafael Trujillo.
They became world champions in 2010 when they beat China at the World Team Table Tennis Championships in Russia, breaking China's 19-year winning streak. In 2021, Singapore's Loh Kean Yew achieved a "World Champion" status when he won a badminton gold at the 2021 BWF World Championships men's singles, which is one of the most prestigious badminton tournaments alongside the Summer Olympics badminton tournaments. Singapore's football league, the Singapore Premier League, was launched in 1996 as the S.League and comprises eight clubs, including one foreign team. The Singapore Slingers is one of the inaugural teams in the ASEAN Basketball League, which was founded in October 2009. Kranji Racecourse is run by the Singapore Turf Club and hosts several meetings per week, including international races—notably the Singapore Airlines International Cup. Singapore began hosting a round of the Formula One World Championship, the Singapore Grand Prix at the Marina Bay Street Circuit in 2008. It was the inaugural F1 night race, and the first F1 street race in Asia. It is considered a signature event on the F1 calendar. ONE Championship was founded in Singapore, a major Mixed Martial Arts (MMA) promotion in Asia.
==== Hierarchical deterministic wallet ==== The hierarchical deterministic (HD) wallet was publicly described in BIP32. As a deterministic wallet, it derives keys from a single master root seed, but instead of having a single "chain" of key pairs, an HD wallet supports multiple independent key pair chains. This allows a single seed to be used to generate an entire tree of key pairs with a stratified structure.
Sources: en.wikipedia.org
=== Firing of employee that filed suit (2010) === A federal lawsuit was filed by a scientist claiming she got an infection by a genetically modified lentivirus while working for Pfizer, resulting in intermittent paralysis. A judge dismissed the case citing a lack of evidence that the illness was caused by the virus but the jury ruled that by firing the employee, Pfizer violated laws protecting freedom of speech and whistleblowers and awarded her $1.37 million.
Side effects are generally similar to other antipsychotics. The drug has a relatively well tolerated side effect profile, with low propensity for QTc interval changes, weight gain and lipid-related adverse effects. In a 2013 meta-analysis of the efficacy and tolerability of 15 antipsychotic drugs, it was found to produce the second least (after haloperidol) weight gain, the least QT interval prolongation, the fourth most extrapyramidal side effects (after haloperidol, zotepine and chlorpromazine), and the sixth least sedation (after paliperidone, sertindole, amisulpride, iloperidone and aripiprazole). As with other atypical neuroleptics, lurasidone should be used with caution in the elderly because it puts them at an increased risk for a stroke or transient ischemic attack; however, these risks are not likely to be greater than those associated with antipsychotics of other classes. Similarly, lurasidone should not be used to treat dementia-related psychosis, as evidence has shown increased mortality with antipsychotic use. Weight gain is reported in up to 15 and 16 percent of users. Other possible side effects include vomiting, akathisia, dystonia, parkinsonism, somnolence, dizziness, sedation and nausea.
The UN later confirmed that Russia was planning to limit registration of ships to the port of Pivdennyi until all parties agreed to unblock the transit of Russian ammonia. The FSB said it had discovered an "intelligence action" that had compromised the phones of Russians as well as diplomats from Israel, Syria, China and NATO members and claimed that Apple had worked with US intelligence agencies such as the National Security Agency in compromising numerous iPhones. Apple did not comment on whether its products in Russia had been hacked but denied working with authorities to compromise its devices. The Pentagon said that it would buy Elon Musk's Starlink satellite service for Ukraine to ensure the continued effectivity of communications in the country. The US State Department said it was revoking the visas of Russian nuclear inspectors, denying pending applications for new monitors and canceling standard clearances for Russian aircraft to enter US airspace in retaliation for Russia's suspension of its participation in the New START treaty. It also said it would no longer notify Russia of any updates on the status or location of "treaty-accountable items" like missiles and launchers. The Swiss National Council voted down, 98–75, a parliamentary initiative put forward by a committee that would have specifically authorized the transfer of Swiss-made arms to Ukraine. Its opponents claimed the proposal was a violation of the country's longstanding policy of neutrality.
=== Sewage treatment === Hydrogen peroxide is used in certain waste-water treatment processes to remove organic impurities. In advanced oxidation processing, the Fenton reaction gives the highly reactive hydroxyl radical (•OH). This degrades organic compounds, including those that are ordinarily robust, such as aromatic or halogenated compounds. It can also oxidize sulfur-based compounds present in the waste; which is beneficial as it generally reduces their odour.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.